Cancer Center Support Grant

项目总结（见说明）： 新泽西癌症研究所（CINJ）作为新泽西唯一的国家癌症研究所（NCI）指定的综合癌症中心，以满足我们国家最多样化和人口最稠密的州之一的癌症研究需求。作为自1997年以来一直由NCI CCSG机制资助的矩阵和财团癌症中心，CINJ进行最先进的研究，患者护理和外展/教育。CINJ目前由来自32个学术部门的161名成员组成，他们拥有超过9290万美元的同行评审支持总额，6110万美元的年度直接支持，2890万美元的NCI支持总额和1870万美元的年度直接NCI支持（自2004年上次提交以来，NCI支持增加了20%）。 自从罗伯特·S·博士被任命以来。DiPaola在2008年9月担任中心主任，研究者发起的治疗性临床试验增加了一倍多;在多个领域招募了17名新教师，包括基础科学，临床科学，公共卫生科学和系统生物学/生物信息学;该联盟 与普林斯顿大学和罗格斯大学的关系得到了加强和正式化;国家癌症登记处和SEER合同被转移到CINJ;并启动了另外四次招聘搜索。CINJ现在有六个已建立的研究项目：细胞死亡和生存信号;基因组不稳定性和肿瘤 增长;癌症药理学和临床前治疗学;临床研究;致癌作用和化学预防;以及癌症预防和控制。CINJ支持14个共享资源，包括：流式细胞术和细胞分选;功能基因组学;转基因和敲除小鼠;药代动力学和 药效学;组织学和成像;生物保藏处;生物信息学;生物识别技术;药学研究;临床研究人员集中教育和培训办公室; 小动物成像（发展中）;代谢组学（发展中）和流行病学服务（发展中）。总体而言，CINJ在NCI指定的中心中具有独特的优势，因为它受益于矩阵癌症中心的机会，同时拥有超越大学矩阵的全州权威，从而建立了一个环境，以促进和正式化大学矩阵内外的跨学科和转化研究的愿景。 我们请求CCSG支持高级领导、项目领导、规划和评估、发展基金、管理、共享资源、方案审查和监测、方案特定研究支持以及数据和安全性监测。

PROJECT SUMMARY (See instructions): The Cancer Institute of New Jersey (CINJ) prevails, as the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to satisfy the cancer research demands of one of the most diverse and densely populated States in our Nation. As a matrix and consortium cancer center that has been continuously funded by the NCI CCSG mechanism since 1997, CINJ conducts state of the art research, patient care, and outreach/education. CINJ is currently comprised of 161 members from a total of 32 academic departments who hold over $92.9 million total peer-reviewed support, $61.1 million annual direct support, $28.9 million total NCI support and $18.7 million annual direct NCI support (a 20% Increase in NCI support since the time of the last submission in 2004). Since the appointment of Dr. Robert S. DiPaola as center director in September, 2008, accrual onto investigator initiated therapeutic clinical trials has more than doubled; 17 new faculty were recruited in multiple areas including Basic Science, Clinical Science, Public Health Science, and Systems Biology/Bioinformatics; the Consortium relationship with Princeton University and Rutgers University was strengthened and formalized; the State's cancer registry and SEER contract was moved to CINJ; and an additional four recruitment searches were launched. CINJ now has six established Research Programs: Cell Death and Survival Signaling; Genomic Instability and Tumor Growth; Cancer Pharmacology and Preclinical Therapeutics; Clinical Investigations; Carcinogenesis and Chemoprevention; and Cancer Prevention and Control. CINJ supports 14 Shared Resources, including: Flow Cytometry and Cell Sorting; Functional Genomics; Transgenic and Knockout Mouse; Pharmacokinetics and Pharmacodynamics; Histopathology and Imaging; Biorepository Service; Bioinformatics; Biometrics; Research Pharmacy; Office of Human Research Services; Centralized Education and Training for Clinical Research Personnel; Small Animal Imaging (developing); Metabolomics (developing) and Epidemiology Services (developing). Overall, CINJ has a unique niche among NCI-designated centers, as it benefits from opportunities as a matrix cancer center and at the same time has State-wide authority beyond the University matrix, thus establishing an environment to foster and formalize a Vision of Transdisciplinary and Translational Research within and beyond the University matrix. We are requesting CCSG support for Senior leadership, Program Leadership, Planning and Evaluation, Developmental Funds, Administration, Shared Resources, Protocol Review and Monitoring, Protocol Specific Research Support, and Data and Safety Monitoring.